-+ 0.00%
-+ 0.00%
-+ 0.00%

Xingqi Pharmaceutical announced that the company recently received the “Drug Clinical Trial Approval Notice” for the SQ-23082 eye drops issued by the State Drug Administration, and approved to carry out clinical trials. This drug is an improved chemical class 2.1 drug. It is intended to be used to treat itchy eyes associated with allergic conjunctivitis. The company has completed pharmaceutical and non-clinical pharmacological toxicology studies.

Zhitongcaijing·09/11/2026 07:49:01
Listen to the news
Xingqi Pharmaceutical announced that the company recently received the “Drug Clinical Trial Approval Notice” for the SQ-23082 eye drops issued by the State Drug Administration, and approved to carry out clinical trials. This drug is an improved chemical class 2.1 drug. It is intended to be used to treat itchy eyes associated with allergic conjunctivitis. The company has completed pharmaceutical and non-clinical pharmacological toxicology studies.